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a b s t r a c t
Dengue is the most important arbovirus in the world with an estimated of 50 million
dengue infections occurring annually and approximately 2.5 billion people living in
dengue endemic countries. Yellow fever is a viral hemorrhagic fever with high mortality
that is transmitted by mosquitoes. Effective vaccines against yellow fever have been
available for almost 70 years and are responsible for a signiﬁcant reduction of occurrences
of the disease worldwide; however, approximately 200,000 cases of yellow fever still occur
annually, principally in Africa. Therefore, it is a public health priority to develop antiviral
agents for treatment of these virus infections. Crotalus durissus terriﬁcus snake, a South
American rattlesnake, presents venom with several biologically actives molecules. In this
study, we evaluated the antiviral activity of crude venom and isolated toxins from Crotalus
durissus terriﬁcus and found that phospholipases A2 showed a high inhibition of Yellow
fever and dengue viruses in VERO E6 cells.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Dengue virus (DENV) and yellow fever virus (YFV),
members of the genus Flavivirus, family Flaviviridae, are
two of the most important arboviruses in public health
(Gould and Solomon, 2008). Dengue is the most rapidly
spreading arbovirus disease in the world. In the last 50
years, incidence has increased 30-fold with increasing
geographic expansion to new countries and, in the present
decade, from urban to rural settings. An estimated 50
million dengue infections occur annually and approxi-
mately 2.5 billion people live in dengue endemic countries
(WHO, 2010). Infectionwith any of the four DENV serotypes
(DENV-1, -2, -3 and -4) can be asymptomatic or can lead to
a wide spectrum of disease, in some cases with fatal
outcome (Harris et al., 2000). YFV is the causative agent of
severe acute hemorrhagic fever with high mortality.
Effective vaccines against yellow fever have been available
for almost 70 years and are responsible for a signiﬁcant
reduction of occurrences of the disease worldwide;
however, approximately 200,000 cases of yellow fever still
occur annually, principally in Africa (Robertson et al., 1996;
WHO, 2010). There is no speciﬁc drug therapy for DENV and
YFV infections; therefore, the development of antiviral
agents to reduce the morbidity and mortality causes by
these two viruses is a public health priority (Hombach
et al., 2005).
Snake venoms are complex mixtures of toxins and
enzymes that show different activities on biological
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systems, such as cytotoxicity, hemorrhage activity,
bradykinin-releasing activity, thrombin-like activity,
hemolysis, cardiovascular and hypotensive effects, tissue
necrosis and neurotoxic effects (Castro et al., 2004;
Debnath et al., 2010; Gutiérrez et al., 2005; Lee, 1977;
Montecucco et al., 2008; Oyama et al., 2008; Vital-Brazil,
1982). The venom of Crotalus durissus terriﬁcus snake,
a South American rattlesnake, has shown several biolog-
ical activities, including antiviral activity against measles
virus (Bercovici et al., 1987; Petricevich and Mendonça,
2003). This venom is composed by neurotoxins, crotoxin
(Slotta and Fraenkel-Conrat, 1938), crotamin (Gonçalves
and Vieira, 1950), phospholipase A2 “inter-cro” (PLA2-IC)
(Vieira, 2009), gyroxin (Alexander et al., 1988) and con-
vulxin (Prado-Franceschi and vital Brazil, 1981). The
fraction which pathophysiological aspects are better
characterized is the crotoxin. It represents 40–60% of the
dry weight of venom and it is the main toxic component
with neurotoxic effects (Faure and Bon, 1988; Vital-Brazil,
1966). This component presents two different subunits no
covalently linked: crotapotin, an acid component with
a molecular weight of w9,000 Da and the phospholipase
A2, a basic component (PLA2-CB) with a molecular weight
of 16,400 Da (Hendon and Fraenkel-Conrat, 1971; Rubsa-
men et al., 1971). Faure et al. (1994) isolated and charac-
terized several isoforms of each subunit of crotoxin in the
venom collected from numerous snakes. Crotoxin is, in
fact, a mixture of variants deriving from the combination
of subunit isoforms. Four crotapotin and four PLA2-CB
present in venom collected from numerous snakes were
puriﬁed and some sequenced (Faure et al., 1991). The
crotapotin isoforms consist of three disulﬁde-linked
polypeptide chains (a, b, g ), which result from different
proteolytic cleavages of a unique precursor pro-crotapotin
that has been identiﬁed from its cDNA. Two cDNAs
encoding PLA2-CB isoforms have been cloned and their
nucleic acid sequences determined (Bouchier et al., 1991).
The PLA2-IC was ﬁrst observed by Laure (1975), but the
enzyme was not isolated or characterized. Vieira (2009)
subsequently isolated and characterized the PLA2-IC
demonstrating that was a new isoform, showing differ-
ences in the C-terminal region when compared with
PLA2-CB1 and PLA2-CB2 (basic chain of crotoxin). The
alignment of the PLA2-CB1, PLA2-CB2 and PLA2-IC
sequences and phylogenetic analysis showed that PLA2-
CB2 isoform showed higher homology with the PLA2-IC
isoform and, furthermore, this homology is greater than
that observed between PLA2-CB1 and PLA2-IC and even
between PLA2-CB1 and PLA2-CB2. The PLA2-CB2 was
originated from the duplication of the PLA2-CB1 gene
(Vieira, 2009). Faure et al. (1994) demonstrated that
the complex PLA2-CB1/CA present in crotoxin, is more
stable than PLA2-CB2/CA association, conﬁrming that
PLA2-IC is an isoform of PLA2-CB2, which does not
make the association with crotapotin but is able to exert
its biological activity present in the venom of C. d.
terriﬁcus.
In this study, we evaluated the antiviral activity of
crude venom and isolated toxins from Crotalus durissus
terriﬁcus and found that phospholipases A2 showed a high
antiviral effect against DENV and YFV.
2. Material and methods
2.1. Cells and viruses
VERO E6 and C6/36 cells were maintained in Leibovitz
medium (L-15) with 10% of fetal bovine serum (FBS) at
37 C and 28 C, respectively. DENV-2 (strain NGC) and YFV
(strain 17D) were used in this study. The viruses were
propagated in C6/36 cells, titrated by plaque formation
assay in VERO E6 cells and expressed in plaque forming
units per milliliters (PFU/mL).
2.2. Venom and isolated toxins
Lyophilized yellow and white crude venom from C. d.
terriﬁcus and crude venom from Bothrops jararacussu were
obtained from the serpentarium of the Medical School of
Ribeirão Preto, São Paulo University (IBAMA authorization:
1/35/1998/000846-1). Crotapotin, crotamin, crotoxin, con-
vulxin, PLA2-CB and PLA2-IC were puriﬁed from C. d. terri-
ﬁcus and BthTX-I from B. jararacussu.
2.3. Toxins puriﬁcation procedure
White crude venom (500 mg) from C. d. terriﬁcus was
fractionated by size exclusion chromatography on Sepha-
dex G-75 column (4.0 110.0 cm) equilibrated with 50mM
ammonium formate, pH 3.5. Elution was carried out using
the same buffer at a ﬂow rate of 30 mL/h. Fractions of
5.0 mL were collected in a fraction collector coupled to an
ultraviolet detector. The absorbance of collected fractions
was determined at 280 nm on a spectrophotometer Beck-
man DU-640 (Beckman, USA). The fractions containing
crotamin, crotoxin, convulxin and PLA2-IC were collected,
dialyzed and lyophilized. The crotoxin (1 g) was dissolved
in 5.0 mL of 50 mM Tris-HCl, pH 7.2, containing 7 M Urea,
and incubated for 12 h at room temperature. In order to
remove urea from the sample, the solution was concen-
trated in an ultraﬁltration apparatus (MILLIPORE, USA)
using a membrane of 10,000 Da. The concentrated sample
was applied into a cationic ion exchange DEAE-Sepharose
column (2.0  24 cm) equilibrated with 50 mM Tris-HCl,
pH 7.2 and 7 M Urea. After the appearance of the ﬁrst
peak, the buffer was changed to 50 mM Tris-HCl, pH 7.2,
containing 0.4 M NaCl. Thus, two fractions were collected,
crotapotin and PLA2-CB. After dialysis, crotapotin and PLA2-
CB were lyophilized (Hendon and Fraenkel-Conrat, 1971).
The fraction PLA2-IC was resuspended in 50 mM
ammonium formate buffer, pH 3.5 and applied to a Sepha-
dex G-75 column pre-equilibrated with 50 mM ammonium
formate buffer, pH 3.5. Finally, the PLA2-IC was resus-
pended in 100 mM ammonium formate buffer, pH 3.5 and
applied into a CM cellulose column (2.5  10.0 cm),
previously equilibrated with the same buffer. In this last
step of puriﬁcation, elution was carried out using the same
buffer at a ﬂow rate of 20mL/h and collected fractions of 5.0
mL/tube. The ammonium formate gradient was increased
gradually and discontinuously (100 mM–2 M). The proof of
the purity of the isolated PLA2 was obtained by RP-HPLC
using a reverse phase C18 column (4.6  100 mm) (Shi-
madzu, Japan), equilibrated with solvent A (5% acetonitrile,
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0.1% triﬂuoroacetic acid) and eluted using a gradient
concentration (0–100%) of solvent B (60% acetonitrile, 0.1%
triﬂuoroacetic acid) at a ﬂow rate of 1.0 mL/min, during
110 min. All puriﬁcation steps were performed at room
temperature and monitored by spectrophotometer at
280 nm (Vieira, 2009).
The protein BthTX-I was puriﬁed from B. jararacussu
according to the method described by Homsi-Brandeburgo
et al. (1988) and Cintra et al. (1993).
2.4. Determination of purity
The purity of crotamin, crotoxin, crotapotin, PLA2-IC and
PLA2-CB was analyzed by SDS-PAGE using a 12.5% poly-
acrylaminde gel. Molecular weight standards were: phos-
phorylase B (97.000), albumin (66.000), ovalbumin (45.000),
carbonic anhydrase (30.000), soybean trypsin inhibitor
(20.000) and lactoalbumin (14.400). Gel was stained with
Coomassie brilliant blue R-250 (Sigma, Germany).
2.5. Enzymatic activity
2.5.1. Phospholipasic activity
The phospholipasic activity of all compounds was per-
formed following the modiﬁed method described by
Gutiérrez et al. (1988). A translucent halo formation around
the hole where the compounds were added in the gel is
indicative of activity.
2.5.2. Myotoxic activity
Crotamin and BthTX-I have showed to present myotoxic
activity; therefore, we determined this activity by the
method previously described by Gutiérrez et al. (1988).
Brieﬂy, 50 mg of the toxins, suspended in PBS (50 mL), were
injected into the right gastrocnemius muscle of Swiss male
mice (18–22 g). Groups of six Swiss mice were used in this
experiment. Control mice group received only PBS. Three
hours after injection, the mice blood was collected in
heparinized capillaries and immediately centrifuged at
3000 g for 10min to obtain the plasma. The activity of the
enzyme creatine kinase (CK) was determined in 4 mL of
plasmausing the kinetic reactive Kit_UVK010 (Bioclin, USA)
following protocol recommended by the manufacturer.
2.6. Cytotoxicity of the compounds
The cytotoxicity of the compounds was evaluated in
VERO E6 cells. Cell viability was measured by MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
(Sigma–Aldrich, Germany) method. Conﬂuent VERO E6
cells monolayers contained in 96-well plates were exposed
to different concentrations of crude venom and isolated
toxins for seven days at 37 C. Then, 50 mL of L-15 con-
taining MTT (ﬁnal concentration 1 mg/mL) was added to
each well. After 4 h of incubation at 37 C, the supernatant
was removed and 100 mL of dimethyl sulfoxide (DMSO) was
added to eachwell to solubilize the formazan crystals. After
shaking, absorbance was measured at 540 nm. The
concentration of each compound necessary to reduce cell
viability in 50% (CC50) was calculated by comparison with
the untreated cells.
2.7. Determination of antiviral activity
The antiviral activity of the venoms and their isolated
toxins was evaluated using several methodological strate-
gies as follows.
2.7.1. Treatment of cells with crude venom and isolated toxins
before viral infection (pre-treatment)
This assay was carried out to determine whether any
crude venom and/or isolated toxin could confer protection
against viral infection. VERO E6 cells (2105 cells/mL/well)
were seeded in a 24-wells plate and incubated at 37 C for
24 h. The medium was removed and the cells were incu-
bated with serial two-fold dilutions (from 100 to
0.01 ng/mL) of crude venom or isolated toxin from C. d.
terriﬁcus. After 3 h of incubation, the supernatant was
removed and cells were infected with 25–100 PFU of virus
contained in 400 mL of L-15 for 1 h. The supernatant was
removed and the cells monolayers were overlaid with 1 mL
of L-15 2 supplemented with 2% FBS and 1.8% carboxy-
methylcellulose. After 7 days at 37 C, the semisolid overlay
mediumwas removed and the cells were ﬁxed and stained
with naphthol blue-black in 5% acetic acid for plaque
counting. Each experiment was repeated three times and
the concentration that inhibited 50% of plaque formation
(Effective Concentration 50%, EC50) was calculated by
comparison with the number of plaque observed in the
untreated cells. The values of CC50 and EC50 were used to
calculate the selectivity index (SI ¼ CC50/EC50), which
suggests the potential antiviral activity of the compounds.
SI with value of four or higher suggests that a compound
have a promising antiviral activity that merit further
studies.
2.7.2. Treatment of cells with crude venom and isolated toxins
after viral infection (post-treatment)
This assay was performed to determine whether the
tested samples inhibited viral replication after cells infec-
tion. VERO E6 cells (2  105 cells/mL/well) were growth in
a 24-well tissue culture plates for 24 h at 37 C. The cells
were infected with 25–100 PFU contained in 400 mL of L-15
and incubated during 1 h at 37 C. The supernatant was
then removed and the cells were covered with 1 mL of
medium overlay containing serial two-fold dilutions of
crude venom or isolated toxin from C. d. terriﬁcus. The
plates were incubated at 37 C for 7 days; then the overlay
medium was removed and the plaques were stained and
counted. EC50 and SI were calculated as described above.
2.7.3. Virucidal activity
The virucidal test evaluates the ability of the crude
venom or isolated toxins to act directly on the viral particle.
Serial two-fold dilutions of crude venom or isolated toxin
from C. d. terriﬁcus were incubated with 25–100 PFU of
each virus for 1 h at 37 C. This mixture was added to
a monolayer of VERO E6 cells to calculate EC50 and SI as
mentioned above.
2.7.4. Evaluation of viral adsorption inhibition
To evaluate the capacity of the compounds to inhibit the
virus adsorption, the viruses were incubated with the cells
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at 4 C. At this temperature the virus adsorbed on the cells
surface but does not internalize. VERO E6 cells (2  105
cells/mL/well) were grown in 24-well tissue culture plates
to reach conﬂuence (24 h). Then, the platewas incubated at
4 C during 30 min, the mediumwas removed and then the
cell monolayers were infected with cool viral suspension
(25–100 PFU/well) and at the same time, each crude venom
or isolated toxins were added at different concentrations.
After 2 h of incubation at 4 C, the supernatant was
removed and the cells were washed with PBS. The cells
were covered with the overlay medium and incubated at
37 C for for 7 days. EC50 and SI were calculated as
described above.
2.7.5. Evaluation of viral internalization inhibition
This assay was performed to evaluate the capacity of the
compounds to inhibit the viral internalization. Conﬂuence
VERO E6 cells (2105 cells/mL/well) were incubated at 4 C
during 30min and then themediumwas removed and cells
were infected with cool viral suspension (25–100 PFU/
well). The infected cells were further incubated at 4 C for
2 h and then washed 3 times with PBS. The cells were
incubated at 37 C for 5 min and immediately treated with
crude venom or isolated toxins at different concentrations
and incubated at 37 C during 1 h. After this period, the
supernatant was removed to wash the cells with citrate
buffer (8.4 g of citric acid, 0.75 g of KCl and 8 g of NaCl in 1 L
– pH ¼ 3,0) and then with PBS. The procedure for plaques
counting and EC50 and SI calculation was carried out as
described above.
3. Results
3.1. Puriﬁcation of toxins from C. d. terriﬁcus and
B. jararacussu
The venom of C. d. terriﬁcus was subjected to size
exclusion chromatography on Sephadex G-75 to obtain the
fractions containing convulxin (I), giroxin (II), crotoxin (III),
PLA2-IC (IV), crotamin (V) and other peptides (VI) (Fig. 1A).
After the ﬁrst chromatographic step, crotoxin fraction was
subjected to a cationic exchange chromatography to obtain
crotapotin (CA) and PLA2-CB (CB) (Fig. 1B). The purity of the
puriﬁed proteins was estimated by SDS-PAGE (Fig. 1C).
In Fig. 1C, crotamim, crotoxin and PLA2-IC (“inter-cro”)
showed only one electrophoretic band indicating the purity
of these proteins. The PLA2-CB toxin (basic chain of cro-
toxin) can be viewed with its CB1 and CB2 isoforms. The
protein BthTX-I was puriﬁed from B. jararacussu according
Fig. 1. Isolation of toxins from Crotalus durissus terriﬁcus snake venom. Sequential puriﬁcation steps: (A) Size exclusion chromatography of crude snake venom
(500 mg) on Sephadex G-75, in 50 mM ammonium formate, ﬂow rate 30 mL/h, 5 mL/tube; (B) re-chromatography of the active fraction (crotoxin) on cationic
exchange in DEAE-sepharose column to purify PLA2-CB (CB) and crotapotin (CA). (C) electrophoretic analysis in SDS-PAGE: (1) C. d. terriﬁcus (yellow venom); (2)
C. d. terriﬁcus (white venom); (3) crotamin; (4) crotoxin; (5) convulxin; (6) PLA2-CB; (7) PLA2–IC; (8) Molecular weight markers.
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to the method described by Homsi-Brandeburgo et al.
(1988) and Cintra et al. (1993).
3.2. Enzymatic activity of the isolated toxins
To show that the different compounds were enzymati-
cally active, we have evaluated the phospholipasic and
myotoxic activities of them.
The crude (yellow and white) venom of C. d. terriﬁcus,
crotoxin, PLA2-CB and PLA2-IC showed phospholipasic
activity (Fig. 2A). Crotamin, crotapotin, convulxin and
BthTX-I did not show any phospholipasic activity.
The myotoxic activity of crotamin and BthTX-I was
evaluated by measuring the levels of creatine kinase in
mice plasma (Fig. 2B). Both compounds showed a signiﬁ-
cant myotoxic activity in mice.
3.3. Cytotoxicity of toxins
The crude venom and isolated toxins of C. d. terriﬁcus did
not show cytotoxicity to 50% (CC50) to VERO E6 cell
monolayers up to a concentration of 500 ng/mL. Based on
the amount of compounds available for the experiments,
100 ng/mL of each compounds were used as maximum
concentration in all the antiviral experiments. BthTX-I
isolated from B. jararacussu venom showed cytotoxicity to
VERO E6 cells with a CC50 of 108.6  8 ng/mL.
3.4. Antiviral activity of crude venoms and toxins of C. d.
terriﬁcus
3.4.1. Pre-treatment
To evaluate the ability of crude venoms and toxins of C.
d. terriﬁcus to confer resistance to VERO E6 cells against
DENV and YFV infection, the cells were treated with serial
two-fold dilutions (from 100 to 0.01 ng/mL) of the
compounds, 3 h before viral infection. Considering that the
compounds did not show cytotoxicity for VERO E6 in the
maximum concentration tested for cytotoxicity (500 ng/
mL), this concentration was considered as the CC50 to
calculate the SI (SI ¼ CC50/CE50) (Table 1). Treatment of the
cells with yellow and white crude venoms, crotoxin, PLA2-
CB and PLA2-IC conferred resistance to the infection against
DENV-2 and YFV. Greater inhibition of viral infection was
Fig. 2. Evaluation of enzymatic activity. (A) Phospholipasic activity of the C. d. terriﬁcus venom and fractions. 1. Crude venom (yellow); 2. Crude venom (white); 3.
Convulxin; 4 Crotoxin; 5. Crotapotin; 6. PLA2-CB; 7. PLA2–IC; 8. Crotamin; 9 BthTX-I. (B) Myotoxic activity of Crotamin and BthTX-I in mice: the increased release
of creatine kinase (CK) in plasma was measured after intramuscular injection of crotamin or BthTX-I (25 mg in 50 mL of PBS) or PBS alone as negative control
(50 mL). The results are expressed as mean  SD (n ¼ 6). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article).
Table 1
Antiviral activity of crude venoms and puriﬁed toxins from C. d. terriﬁcus against YFV and DENV-2 in the pre-treatment assay.
Compounds YFV DENV-2
Inhibition at 100 ng/mL (%) EC50  SD (ng/mL) SI (CC50/CE50) Inhibition at 100 ng/mL (%) EC50  SD (ng/mL) SI (CC50/CE50)
Cdt yellow 100 0.1  0.09 5000 100 0.054  0.004 9259
Cdt white 96 0.19  0.09 2631.6 100 0.067  0.003 7462
Crotoxin 93 0.04  0.04 12500 100 0.05  0.002 10000
Crotapotin 43 WA WA 68 39  2.5 12.8
Crotamin 20 WA WA 11 WA WA
Convulxin 22 WA WA 5 WA WA
PLA2-CB 100 0.26  0.1 1923 100 0.06  0.002 8333
PLA2 – IC 100 1.30  0.6 385 100 0.775  0.09 645
WA: without activity; SD¼ Standard deviation.
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observed when cells were treated with crotoxin, which
showed an SI of 12500 and 10000, against YFV and DENV-2,
respectively. The cells treated with crotapotin showed less
than 50% inhibition of YFV infection, but an inhibition of
68% for DENV-2 leading to an SI of 12.8.
3.4.2. Post-treatment
The crude venoms and isolated toxins were evaluated
for their ability to inhibit the replication of YFV and DENV-2
after the entry of viruses into cells (Table 2). Therefore, the
cells were infected with YFV or DENV-2 and after 1 h the
cells were treated with serial two-fold dilutions (from 100
to 12.5 ng/mL) of the compounds. None of the tested
material was able to inhibit at least 50% of viral replication.
Interestedly, crotoxin, crotapotin, convulxin, PLA2-CB,
PLA2-IC showed an increase of YFV replication and crota-
potin and convulxin of DENV-2.
3.4.3. Virucidal
To verify the capacity of the compounds to inactivate
DENV-2 and YFV by direct effect on the viruses, these were
incubated at room temperature with serial two-fold dilu-
tions (from 100 to 3106 ng/mL) of the compounds for 1 h.
The mixture was used to infect conﬂuent monolayers of
VERO E6 cells (Table 3). Crude venoms (yellow and white),
crotoxin, PLA2-CB and PLA2-IC showed extremely high
inhibition effects against YFV and DENV-2. These results
are similar to those observed in the pre-treatment assay,
suggesting that these compounds inhibit the initial steps of
the viral replication. Therefore, we evaluated the effect of
compounds in the adsorption and internalization of YFV
and DENV-2 in VERO E6 cells.
3.4.4. Adsorption
VERO E6 cells were incubated at 4 C for 30 min and
then treated with serial two-fold dilutions (from 100 to
0.006 ng/mL) of the compounds and infected with YFV or
DENV-2 at the same time. The EC50 and SI were calculated
for each compound (Table 4). The crude venoms (yellow
andwhite) of C. d. terriﬁcus and the isolated toxins crotoxin,
PLA2-CB and PLA2-IC showed high inhibition of both YFV
and DENV-2 infection. However, the isolated toxins crota-
min and convulxin, did not inhibit the replication of DENV-
2, but inhibited the YFV replication, showing SI between 8.4
and 38.
3.4.5. Internalization
To evaluate the effect of crude venom and isolated
toxins from C. d. terriﬁcus in the viral internalization, VERO
E6 were incubated at 4 C and subsequently infected with
YFV or DENV-2. After 2 h at 4 C, the supernatant was
removed and the cells were treated with serial two-fold
dilutions (from 100 to 0.01 ng/mL) of the compounds. The
antiviral activity is shown in Table 5. The crude venoms
(yellow and white), PLA2-CB and crotoxin showed inhibi-
tion of the internalization of YFV and DENV-2; however,
with SI lower than that observed in the inhibition of viral
adsorption. Interestedly, convulxin stimulated the infection
of YFV in 70%.
3.5. Evaluation of the phospholipasic enzymatic activity
The results obtained in most of the methodological
strategies showed that PLA2-CB, PLA2-IC, and crotoxin
were the isolated toxins with the highest antiviral activity.
Crotoxin is constituted by crotapotin and PLA2-CB; thus
the responsible compounds for the antiviral activity of the
C. d. terriﬁcus venom were the phospholipases. Thus,
aiming to evaluate whether the antiviral action of the
phospholipases was related to the catalytic activity, we
analyzed the antiviral activity of BthTX-I, a phospholipase
without catalytic activity, however with high myotoxic
activity isolated from the venom of B. jararacussu. Serial
two-fold dilutions (from 100 to 1.5 ng/mL) of BthTX-I
(CC50 ¼ 108.6 ng/mL) were used in all methodological
strategies. BthTx-I showed antiviral activity in the viru-
cidal, adsorption and internalization assays (Table 6);
however, with SI extremely lower than that observed for
crotoxin, PLA2-CB and PLA2-IC (Table 1, 3 and 4).
Table 2
Antiviral activity of crude venoms and puriﬁed toxins from C. d. terriﬁcus
against YFV and DENV-2 in the pos-treatment assay.
Compounds YFV DENV-2
Inhibition at
100 ng/mL (%)
EC50  SD
(ng/mL)
Inhibition at
100 ng/mL (%)
EC50  SD
(ng/mL)
Cdt yellow 9.5 WA 47 WA
Cdt white 25 WA 33 WA
Crotoxin 34 WA 44 WA
Crotapotin 38 WA 30 WA
Crotamin 9 WA 40 WA
Convulxin 19 WA 36 WA
PLA2-CB 23 WA 47 WA
PLA2-IC 16 WA 15 WA
WA: without activity; SD¼ Standard deviation.
Table 3
Antiviral activity of crude venoms and puriﬁed toxins from C. d. terriﬁcus against YFV and DENV-2 in the virucidal assay.
Compounds YFV DENV-2
Inhibition at
100 ng/mL (%)
EC50  SD (ng/mL) SI (CC50/CE50) Inhibition at
100 ng/mL (%)
EC50  SD (ng/mL) SI (CC50/CE50)
Cdt yellow 100 0.006  0.0008 83333 100 0.005  0.0006 100000
Cdt white 100 0.0045  0.0007 111111 100 0.004  0.0002 125000
Crotoxin 100 0.00045  0.00007 1111111 100 0.001  0.0003 500000
Crotapotin 100 66  29 7.57 100 0.82  0.08 610
Crotamin 14.34 WA WA 33 WA WA
Convulxin 25.5 WA WA 32 WA WA
PLA2-CB 100 0.0037  0.002 135135 100 0.00003  0.000003 16666666
PLA2-IC 100 0.0054  0.0017 92592 100 0.0137  0.005 36496
WA: without activity; SD¼ Standard deviation.
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4. Discussion
Several studies describe the use of natural or synthetic
substances as potential antidengue or antiyellow fever
agents (Benarroch et al., 2004; Poh et al., 2009; Talarico
et al., 2005; Wang et al., 2009; Zhang et al., 2009).
However, currently there is no drug available for treatment
of these infections.
Snake venoms have shown to present antibacterial
(Samy et al., 2010; Wang et al., 2009), antiparasite
(Deolindo et al., 2010), antifungal (Magaldi et al., 2002), and
antiviral activities (Fenand et al., 1999; Petricevich and
Mendonça, 2003); thus, representing a promising source
of antidengue and antiyellow fever compounds.
This study describes the potential antiviral activity
against YFV and DENV of toxins isolated from C. d. terriﬁcus
venom. Crude venoms (yellow and white), crotoxin, PLA2-
CB and PLA2-IC showed a potent inhibition of YFV and
DENV replication in VERO E6 cells and presented high
selectivity indexes. The highest inhibitions of viral repli-
cation were observed in the virucidal, pre-treatment and
adsorption assays indicating that the inhibition occurs at
the initial steps of the replication cycle. Our results suggest
that the antiviral effect showed by C. d. terriﬁcus venomwas
due, mainly, to the phospholipases A2, since PLA2-CB, PLA2-
IC and crotoxin showed a potent inhibitory activity against
YFV and DENV.
Based on their function, localization, regulation, cata-
lytic mechanism and structure, the PLA2 can be divided into
ﬁve groups: secreted PLA2 (sPLA2), cytosolic PLA2 (cPLA2),
Ca2þ-independent PLA2 (iPLA2), PAF acetylhydrolases (PAF-
AH) and lysosomal PLA2 (LPLA2s). The phospholipases of
snake venoms belong to the secreted PLA2 (Dennis, 1997;
Schaloske and Dennis, 2006). They represent a versatile
class of enzymes that occur ubiquitously in nature cata-
lyzing the hydrolysis of the glycerophospholipids at the
sn-2 position releasing free fatty acids and lysophospholi-
pids, playing a key role in various biological activities, such
as lipid digestion, host defense and homeostasis of cellular
membranes (Kini, 2003; Schaloske and Dennis, 2006). We
have found that phospholipases showed the highest anti-
viral activity in the virucidal assay, i.e., act directly on the
virus particle. This result suggests that the enzymatic
activity of the phospholipases is important for the antiviral
effect. To test this hypothesis, we have analyzed the effect
of a phopholipase A2 without catalytic activity (BthTX-I) on
the replication of YFV and DENV. BthTX-I has a substitution
of the aspartate residue at position 49 (Asp49) by a lysine
residue (Lys49), turning this protein with a very low or no
catalytic activity (Cintra et al., 1993). Although BthTX-I
showed antiviral activity in the virucidal, adsorption and
internalization strategies, the SI obtained for this toxin was
extremely lower when compared to the obtained for cro-
toxin, PLA2-CB and PLA2-IC. Therefore, these results suggest
that the enzymatic activity is an important factor for the
antiviral activity. These results are in agreement with
a previous study, which showed that the catalytic function
of a human sPLA2-X was required for antiviral activity
against human immune deﬁciency virus 1 (HIV-1) (Kim
et al., 2007). The importance of sPLA2 catalytic activity in
the antiviral effect was also observed against adenovirus
infection; however, in this case the action was against host
cell membrane (Mitsuishi et al., 2006).
In addition to the catalytic activity, the physiological
function of sPLA2 can be mediated by ligation to speciﬁc
receptors on the cell membrane (Lambeau and Lazdunski,
1999). Thus, this mechanism might also be related to the
antiviral effect showed by sPLA2. In that sense, previous
Table 4
Antiviral activity of crude venoms and puriﬁed toxins from C. d. terriﬁcus against YFV and DENV-2 in the adsorption assay.
Compounds YFV DENV-2
Inhibition at 100 ng/mL (%) EC50  SD (ng/mL) SI (CC50/CE50) Inhibition at 100 ng/mL (%) EC50  SD (ng/mL) SI (CC50/CE50)
Cdt yellow 100 0.037  0.005 13513.5 100 0.07262  0.005 6885
Cdt white 100 0.03608  0.004 13858 100 0.0174  0.003 28735
Crotoxin 100 0.0365  0.004 13698 100 0.018  0.002 27777
Crotapotin 90 13.1  0.1 38 65 53  17 9.4
Crotamin 66 33.7  4.2 14.8 8 WA WA
Convulxin 66 59.3  4.3 8.4 12.6 WA WA
PLA2-CB 100 0.01647  0.004 30358 100 0.044  0.007 11363
PLA2-IC 100 0.268  0.04 1865 100 0.133  0.03 3759
WA: without activity; SD¼ Standard deviation.
Table 5
Antiviral activity of crude venoms and puriﬁed toxins from C. d. terriﬁcus against YFV and DENV-2 in the internalization assay.
Compounds YFV DENV-2
Inhibition at 100 ng/mL (%) EC50  SD (ng/mL) SI (CC50/CE50) Inhibition at 100 ng/mL (%) EC50  SD (ng/mL) SI (CC50/CE50)
Cdt yellow 76 28.7  3.3 17 85 27.7  3.8 18
Cdt white 67 40.6  0.6 12 73 53.9  1.4 9.3
Crotoxin 83 13.7  1.0 36 77 34.4  2.7 14.5
Crotapotin 72 69.9  5.5 7.2 41 WA WA
Crotamin 32 WA WA 46 WA WA
Convulxin 70 WA WA 2.3 WA WA
PLA2-CB 95 3.3  1.0 151 89 17.2  3.3 29
PLA2-IC 46 WA WA 76 21.6  3.4 23
WA: without activity; SD¼ Standard deviation.
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studies have shown that sPLA2 isolated from bee and snake
venom inhibits the entry of HIV-1 in human primary blood
leukocytes, and therefore the replication, through a mecha-
nism linked to the binding of sPLA2 to cells (Fenand et al.,
1999, 2001). In addition, Petricevich and Mendonça (2003),
showed that crude venom of C. d. terriﬁcus inhibit the repli-
cationofmeasles virus onVERO cells, and that this inhibition
occurred at the initial steps of the replication cycle, inde-
pendently of the virucidal effect. Although the higher anti-
viral activityobserved in this studywas in thevirucidal assay,
a high antiviral effect in the pre-treatment assay was also
observed, suggesting that sPLA2 might confer resistance to
VERO E6 cells against infection to DENV-2 and YFV through
of a speciﬁc interaction of sPLA2 to host cells.
In contrast to the inhibitory effect of C. d. terriﬁcus
venom observed in this study, we have also observed that
crotoxin, crotapotin, convulxin, PLA2-CB and PLA2-IC
showed an enhancement of viral infection in the post-
treatment assay, and convulxin in the internalization
assay. More studies are needed to understand the mecha-
nism leading to the enhancement of viral infection.
In summary, we have described the antiviral activity of
sPLA2s of C. d. terriﬁcus venom, which inhibit the infection
of VERO E6 cells by YFV and DENV-2. The inhibition of
viral replication, which might depends on the catalytic
action of the sPLA2s, occurred at the ﬁrst steps of the virus
replication cycle. The results suggest that the PLA2s have
an action on the cells and on the virus particle, which lead
the high antiviral activity seen in this study. Interestedly,
most of the isolated toxin induced an enhancement of
infection when they were added after the virus internali-
zation. These toxins, specially the sPLA2s, could be new
targets to be used as a model for the developing drugs
against DENV and YFV, or for the study of the mechanism
of viral replication.
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